FDA asks company to remove opioid drug from market

Jun 09, 2017 - 02:11 PM

The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
FDA announces recall for certain IV bags
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…
Headline
Recall issued for aspiration system by Q’Apel Medical
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
FDA issues alerts on certain catheters produced by BD, Conavi
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…
Headline
AHA launches online collaborative focused on quality improvement
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
AHA webpage highlights how hospitals and health systems integrate patient safety
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are…
Headline
FDA recalls Medtronic Aortic Root Cannulas 
The Food and Drug Administration has identified a Class I recall of Medtronic Aortic Root Cannulas due to a risk of unexpected loose material in the male luer…